Biogen Inc. (NASDAQ:BIIB) JPMorgan 40th Annual Healthcare Conference January 10, 2022 9:45 AM ET
Company Participants
Michel Vounatsos - Chief Executive Officer
Mike McDonnell - Chief Financial Officer
Priya Singhal - Interim head of R&D
Alisha Alaimo - President, Biogen U.S. Organization
Rachid Izzar - Head of Alzheimer’s Disease and Dementia Business Unit
Conference Call Participants
Cory Kasimov - JPMorgan
Operator
Al right. Thank you and good morning everyone. And once again welcome to the 40th Annual and unfortunately second time virtual JPMorgan Healthcare conference. My name is Cory Kasimov. I am the Senior Large Cap Biotech Analyst and it’s my pleasure to introduce our next company, Biogen, and CEO, Michel Vounatsos.
Please note that following this presentation, we will move right into the Q&A session, where you can send in your questions via the little blue Ask a Question button on your conference portal, and I'll do my best to work them into the conversation. So Michelle, thank you very much for being with us here today. And let me hand things over to you.
Michel Vounatsos
Thank you, Cory. And good morning, everyone and thank you for joining us. Before we begin, next slide. Before we begin, I would like to point out that we'll be making some forward-looking statements. These are based on our current expectations and belief and they contain risks and uncertainties. So I encourage you to consult our SEC filings.
Next slide. Today, I will be also discussing ADUHELM approved by last year by the FDA. So again, I encourage you to look at the full prescribing information included into the ADUHELM.com website.
Next slide. First, let me get started by our priority objective to create new franchises and diversify the company for long term growth and value generation. Biogen has a track record of building new
- Read more current BIIB analysis and news
- View all earnings call transcripts